NCT06243250View on ClinicalTrials.gov

Hyperpolarized 13C-MRI and Metabolomics for Immune-related Adverse Events

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Immune-related Adverse Event
Interventions
DIAGNOSTIC_TEST

Hyperpolarized 13C-MRI

Metabolic MRI using IV injection of hyperpolarized \[1-13C\]pyruvate.

Trial Locations (1)

333

RECRUITING

Chang Gung Memorial hospital, Taoyuan District

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

Chang Gung Memorial Hospital

OTHER